**Company Profile**

**Industry Sector:** Optical sensing devices, software and instrumentation.

**Company Overview:** IOS develops cutting edge-technologies in optical sensing and instrumentation. We take innovative technologies through the development cycle, all the way to fully-functioning independent spin-off companies that focus on physical, chemical, remote sensing, and biological sensing instrumentation.

**Target Market(s):** Point of Care in laboratory, hospital, and doctor’s office settings, as well as high throughput screening for new drug screening.

**Key Value Drivers**

**Technology**: Localized Surface Plasmon Resonance (LSPR) array is a label free detection system that will allow earlier detection of diseases such as ovarian and prostate cancers, faster identification of e-coli and ????.

**Competitive Advantage:** Reduced number of steps over current assay methods; smaller equipment that is easier to use; less cost per test, with the ability to run more tests (multiples of the same test or a variety) at one time

**Plan & Strategy:** Seeking a licensing partner or direct investment for a spin-off company

*Technology funded by the NCI, National Cancer Institute, and being commercialized under the NIH-CAP*

**Management**

**Leadership:**
- John Farina, Chief Executive Officer
- Dr. Robert Lieberman, President
- Aaron Cohen, Chief Operations Officer
- Dr. Lothar Kempen, Chief Technical Officer

**Scientific Investigators:**
- Dr. Glenn Bastiaans, Principal Investigator
- Dr. Srivatsa Rao, Scientist
- Dr. Indu Saxena, Scientist

**Product Development**

**Faster test results and decision making.** We’re targeting a sample-to-answer time under 30 minutes. In a lab setting, this would greatly improve throughput and operational profitability. For comparison purposes, the standard waiting time for results from a CA-125 test can range up to 2 weeks.

**Versatile, economical platform.** Our system will accommodate existing and new assays for a wide variety of target diseases. Our cost-competitiveness would be compelling for running low-margin, high-volume tests.

**Applicability to a variety of user segments.** Collapsing costs and test times would create value for hospitals, clinics, physicians’ offices, emergency responders, and any remote location where rapid test results are needed.

**Portability and ease of use.** The point-of-care version of our system, for clinical or field use, will be automated and self-contained, significantly reducing the need for specialized personnel training.